Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539041 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
A Phase 1 study of Progressive Supranuclear Palsy (PSP), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 12
- Study locations
NCT04539041: Completed Phase 1 study of Progressive Supranuclear Palsy (PSP), sponsored by Novartis Pharmaceuticals.
NCT04539041 is a Phase 1 study of Progressive Supranuclear Palsy (PSP) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 59 participants, below the 687-participant average among 5 other Progressive Supranuclear Palsy (PSP) trials with a reported enrollment target (91% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04539041, a Phase 1 study of Progressive Supranuclear Palsy (PSP), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
Primary Outcome
Adverse events will be collected at clinical visits and other contacts. All abnormalities from safety assessments (physical exams and neurological exams and clinical safety labs) considered clinically significant will be recorded as adverse events
Conditions Studied
Interventions
- DRUG placebo
- DRUG antisense oligonucleotide
Study Locations (12)
Other
- Novartis Investigative Site - Düsseldorf
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - München
- Novartis Investigative Site - Tübingen
- Novartis Investigative Site - Ulm
- Novartis Investigative Site - Southampton
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
California
- University of California San Diego - La Jolla
Minnesota
- Mayo Clinic Rochester - Rochester
Tennessee
- Vanderbilt University Medical CenterX - Nashville
North Rhine-Westphalia
- Novartis Investigative Site - Bonn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 1 |
What the finished NCT04539041 record still lists
NCT04539041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 687-participant average among 5 other Progressive Supranuclear Palsy (PSP) trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Progressive Supranuclear Palsy (PSP) appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT04539041 lists 12 locations in 6 states (Other, Quebec, California).
Frequently Asked Questions
What is clinical trial NCT04539041 about?
NCT04539041 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy". This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
What is the current status of trial NCT04539041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2021-02-16. Estimated completion is 2024-10-17.
What conditions does trial NCT04539041 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy (PSP).
What interventions are being tested in trial NCT04539041?
The interventions under investigation include: placebo (DRUG), antisense oligonucleotide (DRUG).
Who is sponsoring clinical trial NCT04539041?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04539041 being conducted?
This trial has 12 study locations across California, Minnesota, Tennessee, Quebec, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy (PSP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
RECRUITING
-
UPenn Observational Research Repository on Neurodegenerative Disease
RECRUITING
-
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI